0000000000621474

AUTHOR

Bucca C.

showing 2 related works from this author

Persistence of both reversible airway obstruction and higher blood eosinophils may predict lung function decline in severe asthma.

2021

Objective: This study analysed whether the persistence of both reversible airway obstruction (RAO) and elevated BE counts was associated to reduced asthma control and accelerated lung function decline in treated severe asthmatics. Methods: About 202 severe asthmatics were studied after 12–120 months of step-5 treatment associated to anti-IgE therapy. Following treatments, reversibility tests, after inhaling 400 mcg of Salbutamol, were performed. FEV1 > 12% or ≤12% changes differentiated RAO+ from RAO− subjects. Blood eosinophil (BE) counts after treatment were considered. Results: Pre-/post-treatment bronchodilator FEV1% and ACT were lower (61% [50–71], 74.4% [62.5–83.7] and 20[18–22]), …

Pulmonary and Respiratory Medicinesevere asthmamedicine.medical_specialtymedicine.drug_classSevere asthmaEosinophilSettore MED/10 - Malattie Dell'Apparato RespiratorioGastroenterologyPersistence (computer science)03 medical and health sciences0302 clinical medicineInternal medicineBronchodilatorallergic asthma blood eosinophil bronchodilator reversibility lung function decline severe asthma salbutamolForced Expiratory VolumemedicineSettore MED/10Immunology and AllergyHumans030212 general & internal medicineBlood eosinophilLungGenetics (clinical)Lung functionBronchodilator Agentallergic asthma; blood eosinophil; bronchodilator reversibility; lung function decline; severe asthma; salbutamol; bronchodilator agents; eosinophils; forced expiratory volume; humans; lung; airway obstruction; asthmabusiness.industrylung function declineAirway obstructionmedicine.diseaseAsthmaBronchodilator AgentsAirway ObstructionEosinophilsbronchodilator reversibility030228 respiratory systemsalbutamolSalbutamolBlood eosinophilsbusinessallergic asthmamedicine.drugHumanblood eosinophilThe clinical respiratory journalREFERENCES
researchProduct

MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence

2018

mHealth, such as apps running on consumer smart devices is becoming increasingly popular and has the potential to profoundly affect healthcare and health outcomes. However, it may be disruptive and results achieved are not always reaching the goals. Allergic Rhinitis and its Impact on Asthma (ARIA) has evolved from a guideline using the best evidence-based approach to care pathways suited to real-life using mobile technology in allergic rhinitis (AR) and asthma multimorbidity. Patients largely use over-the-counter medications dispensed in pharmacies. Shared decision making centered around the patient and based on self-management should be the norm. Mobile Airways Sentinel networK (MASK), th…

AllergyHEALTH-ORGANIZATIONIMPACTRespiratory Medicine and Allergy[SDV]Life Sciences [q-bio]Allergic Rhinitis and its Impact on Asthma - ARIAReviewMASK - Mobile Airways Sentinel networK0302 clinical medicine610 Medical sciences MedicineApp; ARIA; Asthma; Care pathways; MASK; mHealth; Rhinitis; Immunology and Allergy; Immunology; Pulmonary and Respiratory MedicineHealth careMedicine and Health SciencesImmunology and Allergy030212 general & internal medicineAndroid (operating system)mHealthRinitisRhinitiComputingMilieux_MISCELLANEOUSLungmedicin och allergiRhinitisPRODUCTIVITY3. Good healthALLERGIC RHINITISmHealthRiniteCare pathwaysMedical emergencyLife Sciences & BiomedicinePulmonary and Respiratory MedicineSTRATEGIESMASKMASK study groupImmunologyMEDLINE610K-ANONYMITYPharmacy[object Object]Settore MED/10 - Malattie Dell'Apparato RespiratorioVALIDATIONMACVIA-ARIA03 medical and health sciencesmedicineMobile technologyTECHNOLOGYApp -MASKApp ; ARIA ; Asthma ; Care pathways ; MASK ; mHealth ; RhinitisARIA; App; Asthma; Care pathways; MASK; Rhinitis; mHealthAsmaAsthmaCare pathwayScience & TechnologyARIAbusiness.industryApp; ARIA; Asthma; Care pathways; MASK; mHealth; RhinitisSettore MED/09 - MEDICINA INTERNACorrectionGuidelineRC581-607medicine.diseaseAsthma030228 respiratory systemImmunologic diseases. AllergybusinessAppEUROPEAN COUNTRIES[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct